Clinical trials: BRCA 1/2
Women With BRCA 1 or BRCA 2 Mutation, Non-tested Female Family Members
Lessons Learned From the Family Gene Toolkit
Mutations in the BRCA1/2 genes are the primary cause of hereditary breast/ovarian cancer syndrome. Genetic testing identifies mutation carriers and enables them to manage their cancer risk (i.e.
- Trial name
- FGT (NCT02154633)
- Testing
- Family Gene Toolkit, Delayed Family Gene Toolkit
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- University of Michigan
BRCA Mutation, Ovarian Cancer
Prediction of Germline BRCA 1/2 Genes From Healthy Ovaries
The project aims at enhancing performance metrics and prospectively validating a radiogenomics model based on ovarian US images for predicting germline breast cancer susceptibility gene 1 and/or 2 (BRCA) status in women with…
- Conditions
- BRCA Mutation, Ovarian Cancer, Ultrasound Therapy; Complications
- Trial name
- PROBE-II (NCT05769517)
- Testing
- Germinal BRCA
- Where
- Italy
- Volunteers
- 6,465 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Breast Cancer
Genetic Risk Estimations for Influencing Decision Making in Women at High Risk of Breast Cancer, GENRE 2 Study
The primary aim of this study is to determine if the addition of an individual polygenic risk score (PRS) in addition to the Breast Cancer Risk Assessment Tool (BCRAT) or Tyrer-Cuzick (IBIS) score will aid women at risk of breast…
- Trial name
- GENRE2 (NCT04474834)
- Testing
- Polygenic Risk Score
- Where
- 5 sites in United States
- Volunteers
- 737 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Ovarian Diseases
Feasability Study of Removing the Ovaries and Fallopian Tubes
The main reason for this trial is to show the feasibility of removing the ovarien and fallopian tubes through the gaster (transgastric adnexectomy).
- Trial name
- TG-Adnex (NCT01566955)
- Testing
- transgastric adnexectomy
- Where
- Germany
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Heidelberg University
Hereditary Breast and Ovarian Cancer Syndrome
Search Allelic Imbalance of Expression of BRCA Genes in Hereditary Risk of Breast and/or Ovarian Cancer
The purpose of this study is to determine proportion of patients presented a search allelic imbalance of expression of genes BRCA 1 and 2 in population with hereditary breast and/or ovarian cancer risk and negative for deletion…
- Trial name
- EXSAL (NCT01333748)
- Testing
- blood collection
- Where
- 6 sites in France
- Volunteers
- 530 people, healthy volunteers welcome
- Sponsor
- Centre Francois Baclesse
Ovarian Cancer Prevention
ASA in Prevention of Ovarian Cancer (STICs and STONEs)
While ASA is not a cancer medication, research suggests that taking ASA reduces the probability of getting many types of cancer because of its anti-inflammatory action.
- Trial name
- NCT03480776
- Testing
- Acetylsalicylic acid
- Where
- 17 sites in Australia, Canada
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Canadian Cancer Trials Group
Candidates for BRCA 1/2 Genetic Testing
A Study of the Communication of Genetic Test Results By Telephone: A Multi-Center Study
The overall goal of the proposed research is to evaluate psychosocial and behavioral outcomes (i.e.risks and benefits) of an innovative and efficient delivery model for genetic testing, telephone communication, as an alternative…
- Trial name
- NCT01736345
- Testing
- Genetic Providers, Visual Aids, Post-Disclosure Asessments
- Where
- 5 sites in United States
- Volunteers
- 289 people, healthy volunteers welcome
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Cancer
One-stage Breast Reconstruction Using Dermal Matrix/Implant Versus Two-stage Expander/Implant Procedure
Currently the two-stage tissue expander/implant (TE/I) technique is the standard breast reconstructive option for breast cancer patients selected for immediate, skin-sparing mastectomy.
- Trial name
- AllodermRCT (NCT00956384)
- Testing
- One-stage dermal matrix/implant procedure, Two-stage tissue expander/implant procedure
- Where
- 4 sites in Canada
- Volunteers
- 198 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
BRCA1 Gene Mutation, BRCA2 Gene Mutation
Transformation Potential of E2 Exposed Breast Cancer Susceptibility Gene Mutation Heterozygous Epithelial Breast Cells
Susceptibility to breast cancer is related to the combination of genetic, hormonal and multiple other environmental risk factors, such as mutations in the BRCA gene and excess exposure to exogenous estrogen, respectively.
- Trial name
- NCT01907438
- Where
- Israel
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hadassah Medical Organization